2002 Fiscal Year Final Research Report Summary
REDUCTION OF ISCHEMIA-REPERFUSION INJURY TO SKIN FLAP MODEL BY MONOCLONAL ANTIBODY TO ADHESION MOLECULE-EXPERIMENTAL STUDY-
| Project/Area Number |
12671752
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Plastic surgery
|
|---|
| Research Institution | SHOWA UNIVERSITY |
|---|
Principal Investigator |
TOSA Yasuyoshi SHOWA UNIVERSITY, Department of Plastic Surgery, AssistantProfessor (60296986)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SATOH Kaneshige Showa University, Department of Plastic Surgery, Professor (50138442)
HOSAKA Yoshiaki Showa University, Department of Plastic Surgery, Professor (40156998)
|
|---|
| Project Period (FY) |
2000 – 2002
|
| Keywords | MONOCLONAL ANTIBODY / ISCHEMIA-REPERFUSION INJURY / SKIN FLAP MODEL / ANTIBODY TO LECAM-1 / ANTIBODY TO VLA-4 / ANTIBODY TO VCAM-1 / TACROLIMUS / Sptrague-Dawley RAT |
|---|
| Research Abstract |
Aim : Ischemia-reperfusion(I-R) injury continues to be a problem for successful free tissue transfer and replantation after prolonged periods of ischemia. It has been shown that leukocytes and vascular endothelial cells release a variety of inflammatory mediators during reperfusion after ischemia. The vascular cell adhesion molecule-1 (VCAM-1) is a ligand on the endothelium for some of the adhesion receptors on leukocytes. The purpose of this study was to evaluate the blockage of leukocyte-endothelial adhesion by a monoclonal antibody (MAb) to VCAM-1/VLA-4, Tacrolimus, LECAM-1 in skin flaps to prevent I-R injury in rats.
Methods : Male SD rats (225-250gr) were used. A skin flap (45×30mm) supplied by the superficial epigastric A&V including the femoral vessels was isolated unilaterally. The femoral vessels were cross-clamped the epigastric vessels for 9 hours of ischemia. Animals in treated group received MAb to VCAM-1/VLA-4, Tacrolimus, LECAM-1 i.v. 15 minutes prior to reperfusion ; those in the control group received normal saline. Skin flap viability was assessed by tracing the outline of viable and nonviable areas. Data were collected for the following 7 days. These data were corroborated with histological evidence on comparable areas of the flap.
Results : Tracing analysis revealed average flap survival area of about 70% in treated group and about 20% in control group (p<0.05). Histopathologically, few inflammatory changes could be observed in treated group, while marked damage was observed in control group.
Conclusions : From this study, we concluded that treating skin flaps with Mab to VCAM-1, Tacrolimus, LECAM-1 was effective for I-R injury after 9 hours of warm ischemia.
|
Research Products
(10 results)
